(Techsonian) –PennyStockParlay.com Our process for picking penny stocks is not only unconventional, but untapped, undiscovered, and also exclusive. To keep our picks consistent with how only the “Best Penny Stocks” perform in the penny stock market, we have to keep our penny stock picks producing large and consistent gains.Have a look at today’s active stocks:Medbox Inc (OTCMKTS:MDBX), Mongolia Growth Group Ltd. (OTCMKTS:MNGGF), Affymax, Inc. (OTCMKTS:AFFY), Advanced Cell Technology, Inc. (OTCBB:ACTC)
Medbox Inc (OTCMKTS:MDBX) remained a volume gainer of 5,530 shares and the average volume of the stock remained 14,939 shares. The stock opened the session at $26.26 and was recently trading at $27.50 and the stock advanced 2.96 %. The market capitalization of the stock remained 394.64 million. The half-yearly trend of the stock remained positive 4.88%. Medbox Inc. (Medbox) offers a machine that dispenses medication to individuals based on biometric identification (fingerprint sample). The machine allows pharmacies, hospitals, doctors’ offices, and alternative medicine clinics to manage employee possession of sensitive drugs.
Why Should Investors Buy MDBX After The Recent Gain? Just Go Here and Find Out
In the recent trading session, Mongolia Growth Group Ltd. (OTCMKTS:MNGGF) traded 700 shares and the average volume of the stock remained 32,220 shares. The 52 week range of the stock remained $2.03 – $4.58. The stock was a bull and advanced 2.56 %, while its trading price stayed at $2.28. The market capitalization of the stock remained 64.80 million. The half-yearly trend of the stock remained negative -39.52%.
What was the Moving Force behind MNGGF on Bullish Run? Read This Research Report
Affymax, Inc. (OTCMKTS:AFFY) recently declined -4.69% and was moving within a range of $1.21-$1.28. Its current trading price is $1.22. The share price hit its 52-week low of $0.78 and $27.74 was the best price. The stock completed the day with a total volume of 215,808 shares, versus an average volume of 848,796 shares. Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells.
Will AFFY Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Advanced Cell Technology, Inc. (OTCBB:ACTC) gained volume of 3.15 million shares, while the average volume remained 9.37 million shares. The stock remained at $0.0679. The EPS of the stock remained -0.01. The one month trend of the stock was 6.93% and the three month trend remained negative -14.05%. Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.
Should ACTC a Buy or Sell Now? Find Out Here
Penny stocks are stocks that can be traded in the stock market at a very cheap price. The investor who decides to buy penny stocks should have a substantial intellect of the market and should be bequeathing to possibly suffer a loss in money. The phrase penny stock is usually used for stock dealing that does not imply the greater and popularly known exchanges.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the PennyStockParlay.comnewsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
PennyStockParlay.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies in the profiled on the PennyStockParlay.com web site and/or newsletter involve a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock.
Read Full Disclaimer at: http://pennystockparlay.com/disclaimer.html